OSE Immunotherapeutics Company Profile

18:16 EDT 26th March 2019 | BioPortfolio

News Articles [47 Associated News Articles listed on BioPortfolio]

IRX Therapeutics acquired by Brooklyn ImmunoTherapeutics

This name reflects the company’s focus on advancing the science of cytokine-based immunotherapy for the treatment of a range of cancers. Brooklyn ImmunoTherapeutics general partner and board chair ...

OSE Immunotherapeutics to study cancer drug in France and Belgium

OSE Immunotherapeutics has secured authorisation from the French and Belgian regulatory authorities to conduct a Phase I clinical trial evaluating...Read More... The post OSE Immunotherapeutics to stu...

Deals this week: OSE Immunotherapeutics, Tango Therapeutics, Provention Bio

OSE Immunotherapeutics has received global rights to autoimmune disease candidate FR104 from Janssen Biotech. The drug was licensed to Janssen...Read More... The post Deals this week: OSE Immunotherap...

OSE Immunotherapeutics to Present at Biotech Showcase 2019 Conference

During JP Morgan Healthcare ConferenceSan Francisco, January 7-9, 2019 Regulatory News: OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) (Paris:OSE), today announced that Alexis Peyroles, C...

Janssen returns FR104 global rights to OSE Immunotherapeutics

Janssen Biotech has returned the global rights to its autoimmune disease asset, FR104, to French pharmaceutical company OSE Immunotherapeutics. Effective...Read More... The post Janssen returns FR104 ...

OSE Immunotherapeutics Presents its Novel Bispecific Checkpoint Inhibitor Platform, Targeting PD-1 and Innovative Targets

At the 2019 World Immunotherapy Congress Regulatory News: OSE Immunotherapeutics (Paris:OSE) (ISIN: FR0012127173; Mnémo: OSE), announces that it has disclosed its novel bispecific checkpoint inhib...

OSE Immunotherapeutics (OSE) - Immunotherapy research engine

Edison Investment Research - Pharmaceutical & healthcare - OSE Immunotherapeutics : OSE Immunotherapeutics (OSE) is a drug developer that focuses on both oncology and immune disorders, with an R&D...

OSE Immunotherapeutics Presents Selective SIRP-alpha antibodies: OSE-172, a next-generation myeloid checkpoint inhibitor at the World Immunotherapy Congress

Basel, Oct. 29-31, 2018 OSE Immunotherapeutics SA (Paris:OSE) (ISIN: FR0012127173; Mnémo: OSE) presented at the World Immunotherapy Congress held on Oct. 29-31, 2018 in Basel, Switzerland. Bernard...

Drugs and Medications [0 Results]


PubMed Articles [114 Associated PubMed Articles listed on BioPortfolio]

Human Vaccines & Immunotherapeutics awards top reviewer of the year.

Human Vaccines & Immunotherapeutics: News.

Human Vaccines & Immunotherapeutics: news.

Perspective: cancer vaccines in the era of immune checkpoint blockade.

Current excitement about cancer immunotherapy is the result of unprecedented clinical impact from immune checkpoint inhibitors, particularly those that target programmed death (PD)-1 and PD-ligand (L)...

Vaccine-Based Immunotherapeutics for the Treatment of Glioblastoma: Advances, Challenges, and Future Perspectives.

Glioblastoma is a highly aggressive neoplasm with an extremely poor prognosis. Despite maximal gross resection and chemoradiotherapy, these grade IV astrocytomas consistently recur. Glioblastoma cells...

Clinical Trials [2 Associated Clinical Trials listed on BioPortfolio]

Cabozantinib in Combination With Durvalumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA)

The investigators propose to evaluate cabozantinib in combination with durvalumab in previously treated patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malig...

Personalized Immunotherapeutics for Antibiotic-resistant Infection

M. A. suffers from hypogammaglobulinemia that has been complicated by refractory Mycoplasma hominis septic arthritis. He has been receiving the antibiotic valnemulin under Emergency Invest...

Companies [24 Associated Companies listed on BioPortfolio]

Brooklyn ImmunoTherapeutics LLC

Brooklyn ImmunoTherapeutics (formerly IRX Therapeutics) is focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, both as a single ag...

Innate Immunotherapeutics Limited

Innate Immunotherapeutics Limited is a public unlisted biopharmaceutical company based in Auckland, New Zealand. The company is focused on the development of a new generation of i...

Selexis SA and OSE Immunotherapeutics SA

Our ambition is to become a world leader in activation and regulation immunotherapies: OSE Immunotherapeutics is a biotechnology company led by world-class immunologists and focus...

OSE Immunotherapeutics

Artielle ImmunoTherapeutics

More Information about "OSE Immunotherapeutics" on BioPortfolio

We have published hundreds of OSE Immunotherapeutics news stories on BioPortfolio along with dozens of OSE Immunotherapeutics Clinical Trials and PubMed Articles about OSE Immunotherapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of OSE Immunotherapeutics Companies in our database. You can also find out about relevant OSE Immunotherapeutics Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record